# Monitoring of donor chimerism in sorted CD34+ peripheral blood cells allows the sensitive detection of imminent relapse after allogeneic stem cell transplantation

Martin Bornhäuser,[1] Uta Oelschlaegel,[1] Uwe Platzbecker,[1] Gesine Bug,[2] Karin Lutterbeck,[1] Michael G. Kiehl,[3] Johannes Schetelig,[1] Alexander Kiani,[1] Thomas Illmer,[1] Markus Schaich,[1] Catrin Theuser,[1] Brigitte Mohr,[1] Cornelia Brendel,[4] Axel A. Fauser,[3] Stefan Klein,[2] Hans Martin,[2] Gerhard Ehninger,[1] and Christian Thiede[1]

[1]Medizinische Klinik und Poliklinik I, University Hospital, Dresden, Germany; [2]Medizinische Klinik II, Hematology/Oncology, Frankfurt, Germany; [3]Bone Marrow Transplantation Clinic, Idar Oberstein, Germany, and [4]Klinik für Innere Medizin, Schwerpunkt Hämatologie/Onkologie, Marburg, Germany

Online Supplementary Figure 1. Paired analysis of donor chimerism in CD34+ peripheral blood and CD34+ BM cells. The graph shows results of donor chimerism analysis in CD34 sorted peripheral blood (PBL, filled triangles) *vs.* bone marrow (BM, filled squares) samples taken from the same patient on the same day. Both PBL and BM values of each patient are connected by a line.

Online Supplementary Table 1. Patient characteristics.

Characteristic	
Disease	**N (%)**
-AML	67 (74)
-ALL	16 (18)
-MDS	7 (8)
Cytogenetics/ Molecular marker	
- Normal karyotype	37 (41)
- Numeric aberration/Deletion	18 (20)
- Translocation/Inversion	22 (24)
- Inversion 16	6 (7)
- Bcr/abl (ALL)	5 (6)
- unknown	13 (15)
Median age (range)	43 (7-68)
Sex	
-Male	49 (54)
-Female	41 (46)
Donor	
-Sibling	35 (39)
-Unrelated	55 (61)
HLA match	
-Matched*	76 (85)
-Mismatch	12 (13)
-Haploidentical	2 (2)
Risk category	
-Low risk+	42 (47)
-High Risk#	48 (53)
Graft soucre	
-Peripheral blood	82 (91)
-Bone marrow	8 (9)
Conditioning therapy	
-Intensive	50 (56)
-Reduced intensity	40 (44)

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; *, A, B, C, DRB1 and DQB1 allele matched; +, AML/ALL in 1st or 2nd complete remission and MDS with ≤ 5% blasts; # AML/ALL > 2nd CR or not in remission and MDS > 5% blasts.

Online Supplementary Table 2. Cox regression models.

Outcome	Risk factor	Hazard ratio	95% CI	p-value
Probability of relapse	Risk group (High vs. low)	2.4	1.1-5.3	0.03
	CD34+ chimerism < 80%	3.5	1.5-7.8	0.003
Overall survival	Risk group (High vs. low)	2.4	1.2-4.6	0.01
	CD34+ chimerism < 80%	1.9	1.0-3.5	0.05
Diseae-free survival	Risk group (High vs. low)	2.4	1.3-4.5	0.06
	CD34+ Chimerism < 80%	2.4	1.3-4.6	0.08

AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; MDS: myelodysplastic syndrome; *, A, B, C, DRB1 and DQB1 allele matched; +, AML/ALL in 1st or 2nd complete remission and MDS with ≤ 5% blasts; # AML/ALL > 2nd CR or not in remission and MDS > 5% blasts.